Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines

Title: Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
Authors: Anne Huber; Amr Allam; Christine Dijkstra; Stafan Thiem; Jennifer Huynh; Ashleigh Poh; Joshua Konecnik; Saumya P Jacob; R Busuttil; Yang Liao; David Chisanga; Wei Shi; Mariah Grace Alorro; S Forrow; DVF Tauriello; E Batlle; A Boussioutas; David Williams; Michael Buchert; Matthias Ernst; Moritz Eissmann
Publication Year: 2024
Collection: La Trobe University (Melbourne): Figshare
Subject Terms: Biological sciences; Biochemistry and cell biology; Oncology and carcinogenesis; TP53; gastric carcinoma; STAT3; cytokine signaling; animal model; organoids; interleukin-6; interleukin-11; metastasis; WNT
Description: Although aberrant activation of the KRAS and PI3K pathway alongside TP53 mutations account for frequent aberrations in human gastric cancers, neither the sequence nor the individual contributions of these mutations have been clarified. Here, we establish an allelic series of mice to afford conditional expression in the glandular epithelium of KrasG12D;Pik3caH1047R or Trp53R172H and/or ablation of Pten or Trp53. We find that KrasG12D;Pik3caH1047R is sufficient to induce adenomas and that lesions progress to carcinoma when also harboring Pten deletions. An additional challenge with either Trp53 loss- or gain-of-function alleles further accelerated tumor progression and triggered metastatic disease. While tumor-intrinsic STAT3 signaling in response to gp130 family cytokines remained as a gatekeeper for all stages of tumor development, metastatic progression required a mutant Trp53-induced interleukin (IL)-11 to IL-6 dependency switch. Consistent with the poorer survival of patients with high IL-6 expression, we identify IL-6/STAT3 signaling as a therapeutic vulnerability for TP53-mutant gastric cancer.
Document Type: article in journal/newspaper
Language: unknown
DOI: 10.26181/26981509.v1
Availability: https://doi.org/10.26181/26981509.v1; https://figshare.com/articles/journal_contribution/Mutant_TP53_switches_therapeutic_vulnerability_during_gastric_cancer_progression_within_interleukin-6_family_cytokines/26981509
Rights: CC BY 4.0
Accession Number: edsbas.2B21A690
Database: BASE